

## REFERENCES

1. Weiss U. Inflammation. *Nature* 2008; 454: 427.
2. Sturtino V, Jakubovsky J, Hulin K. Inflammation and fever. In: *Pathophysiology Principles of Diseases (Textbook for Medical Students)* [online]. Available: <http://www.savba.sk/logos/books/scientific/Inffever.html> [1995, January 19].
3. Burke A, Smyth E, FitzGerald GA. Analgesic-antipyretic agents; pharmacology of gout. In: Brunton LL, Lazo JS, Parker KL, editors. *Goodman & Gilman's the pharmacological basis of therapeutics* 11th ed. New York, McGraw-Hill, 2006; pp. 671-716.
4. Davies P, Bailey PJ, Goldenberg MM. The role of arachidonic acid oxygenation products in pain and inflammation. *Annual review of immunology* 1984; 2: 335-357.
5. Fantone JC, Ward PA. Inflammation. In: Rubin E, Farber JL, editors. *Pathology*. 3rd ed. Philadelphia: Lippincott, 1999; pp. 36-75.
6. Kumar V, Abbas AK, Fausto N, editors. *Acute and chronic inflammation*. Robbins & Cotran *Pathologic Basis of Disease* 7th ed. Philadelphia: Elsevier Saunders, 2005; pp. 48-85.
7. Karsten G. Lipid autacoids in inflammation and injury responses; a matter of privilege. *Molecular interventions* 2008; 8: 28-35.

8. Kuijpers TW, Hakkert BC, Hart MHL, Roos D. Neutrophil migration across monolayers of cytokine-prestimulated endothelial cells: a role for platelet-activating factor and IL-8. *The Journal of cell biology* 1992; 117: 565-572.
9. Collins T. Acute and chronic inflammation. In: Cotran RS, Kumar V, Collins T, editors. *Robbins Pathologic Basis of Disease* 6th ed. Philadelphia: WB Saunders, 1999; pp. 50-88.
10. Armstrong EJ, Klickstein LB. Principles of inflammation and the immune system. In: Golan DE, Tashjian AH, Armstrong EJ, Armstrong AW; editors. *Principles of pharmacology: The pathophysiologic basis of drug therapy* 2nd ed. Lippincott: Williams & Wilkins, 2008; pp. 735-745.
11. Vane JR. Prostaglandins in the inflammatory response. In: Lepow IH, Warol PA, editors. *Inflammation: Mechanism and control*. New York: Academic press, 1972; pp. 261-231.
12. Rang HP, Dale MM, Ritter JM. Other peripheral mediators: 5-hydroxytryptamine and purines. In: Rang HP, Dale MM, Ritter JM, editors. *Pharmacology* 3rd ed. Edinburgh: Churchill Livingstone, 1995; pp.177-190.
13. Galli SJ. New concepts about the mast cell. *The New England journal of medicine* 1993; 328: 257-265.
14. Spector WG. Substances that affect capillary permeability. *Pharmacological reviews* 1958; 10: 475-505.
15. Nichols DE, Nichols CD. Serotonin receptors. *Chemical reviews* 2008; 108: 1614-1641.
16. Roth BL, Chuang DM. Multiple mechanisms of serotonergic signal transduction. *Life sciences* 1987; 41: 1051-1064.

17. MoËssner R, Lesch KP. Role of serotonin in the immune system and in neuroimmune interactions. *Brain, behavior, and immunity* 1998; 12: 249-271.
18. Benedict CR, Mathew B, Rex KA, Cartwright J, Sordahl LA. Correlation of plasma serotonin changes with platelet aggregation in an *in vivo* dog model of spontaneous occlusive coronary thrombus formation. *Circulation research* 1986; 58: 58-67.
19. Mongar JL. Complement. In: Dale MM, Foreman JC, editors. *Text book of Immunopharmacology* 2nd ed. London: Black well Scientific 1989: 149-156.
20. Cooper NR. Biology of the complement system. In: Gallin JI, Snyderman R, editors. *Inflammation. Basic principles and clinical correlates* 3rd ed. Philadelphia: Lippincott Williams and Wilkins, 1999; pp. 281-315.
21. Zachariae H, Malmquist J, Oates JA, Pettinger W. Study on the mechanism of kinin formation. *The Journal of physiology* 1967; 190: 81-90.
22. Murphy HS. Inflammation. In: Rubin R, Strayer DS, editors. *Rubin's Pathology* 5th ed. Philadelphia: Lippincott Williams and Wilkins, 2008; pp. 43-45.
23. Reid IA. Vasoactive peptides. In: Kataung BG, editor. *Basic and clinical pharmacology* 8th ed. New York: McGraw-Hill companies, 2001; pp. 292-325.
24. Beck PW, Handwerker HO. Bradykinin and serotonin effects on various types of cutaneous nerve fibres. *Pflügers Archiv: European journal of physiology* 1974; 347: 209-222.

25. Cunnion KM, Wagner E, Frank MM. Complement and kinin. In: Parslow TG, Stites DP, Terr AL, Imboden JB; editors. Medical immunology 10th ed. New York: McGraw-Hill Companies, 2001; pp. 175-188.
26. Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. Pharmacological reviews 1998; 50: 357-386.
27. Ahluwalia A, Perretti M. Involvement of bradykinin B1 receptors in the polymorphonuclear leukocyte accumulation induced by IL-1 beta in vivo in the mouse. Journal of immunology 1996; 156: 269-274.
28. McLean PG, Ahluwalia A, Perretti M. Association between kinin B1 receptor expression and leukocyte trafficking across mouse mesenteric postcapillary venules. The Journal of experimental medicine 2000; 192: 367-380.
29. Duchene J, Lecomte F, Ahmed S, Cayla C, Pesquero J, Bader M, Perretti M, Ahluwalia A. A novel inflammatory pathway involved in leukocyte recruitment: role for the kinin B1 receptor and the chemokine CXCL5. Journal of Immunology 2007: 4849-4856.
30. Katzung BG, Julius DJ. The Eicosanoids: Prostaglandins, Thromboxanes, Leukotrienes, & Related Compounds. In: Katzung BG; editor. Basic and clinical pharmacology 9th ed. Sanfrancisco: Lange medical book/McGraw-Hill companies, 2004; pp. 434-456
31. Smyth EM, Burke A, FitzGerald GA. Lipid-derived autacoids: eicosanoids and platelet-activating factor. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's the pharmacological basis of therapeutics 11th ed. New York: McGraw-Hill, 2006; pp. 653-670.

32. Wolfe LS. Eicosanoids: prostaglandins, thromboxanes, leukotrienes, and other derivatives of carbon-20 unsaturated fatty acids. *Journal of neurochemistry* 1982; 38: 1-14.
33. Meade EA, Jones DA, Zimmerman GA, McIntyre TM, Prescott SM. Prostaglandins and related compounds: lipid messengers with many actions. In: Bell RM, Exton JH, Prescott SM, editors. *Handbook of lipid research, lipid second messengers volume 8*. New York: Plenum Press, 2007; 285.
34. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. *The Journal of biological chemistry* 1996; 271: 33157-33160.
35. Samad TA, Sapirstein A, Woolf CJ. Prostanoids and pain: Unraveling mechanisms and revealing therapeutic targets. *Trends in molecular medicine* 2002; 8: 390-396.
36. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, Isakson P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. *Proceedings of the National Academy of Sciences of the United States of America* 1994; 91: 12013-12017.
37. Masferrer JL, Zweifel BS, Colburn SM, Ornberg RL, Salvemini D, Isakson P, Seibert K. The role of cyclooxygenase-2 in inflammation. *American journal of therapeutics* 1995; 2: 607-610.
38. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. *The New England journal of medicine* 2001; 345: 433-442.
39. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other

analgesic/antipyretic drugs: cloning, structure, and expression. Proceedings of the National Academy of Sciences of the United States of America 2002; 99: 13926-13931.

40. Schwab JM, Schluesener HJ, Meyermann R, Serhan CN. COX-3 the enzyme and the concept: Steps towards highly specialized pathways and precision therapeutics? Prostaglandins, leukotrienes, and essential fatty acids 2003; 69: 339-343.
41. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annual review of pharmacology and toxicology 1998; 38: 97-120.
42. Wissner A, Schaub RE, Sum PE, Kohler CA, Goldstein BM. Analogues of platelet activating factor 4. Some modifications of the phosphocholine moiety. Journal of medicinal chemistry 1986; 29: 328-333.
43. Issekutz AC, Szpejda M. Evidence that platelet activating factor may mediate some acute inflammatory responses. Laboratory investigation; a journal of technical methods and pathology 1986; 54: 275-281.
44. Vargaftig BB, Braquet PG. PAF-acether today-relevance for acute experimental anaphylaxis. British medical bulletin 1987; 43: 312-335.
45. Ferguson-Chanowitz K, Katocs A, Pickett W, Kaplan J, Sass P, Oronsky A, Kerwar S. Platelet-activating factor or a platelet-activating factor antagonist decreases tumor necrosis factor in the plasma of mice treated with endotoxin. The Journal of infectious diseases 1990; 162: 1081-1086.
46. Imaizumi TA, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM, Zimmerman GA. Platelet-activating factor: a mediator for clinicians. Journal of internal medicine 1995; 238: 5-20.

47. Hwang SB, Li CL, Lam MH, Shen TY. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor antagonist. *Laboratory investigation; a journal of technical methods and pathology* 1985; 52: 617-630.
48. Kushner I. Regulation of the acute phase response by cytokines. *Perspectives in biology and medicine* 1993; 36: 611-622.
49. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. *Annual review of immunology* 1993; 11: 767-804.
50. Ramilo O, Saez-Llorens X, Mertsola J. Tumor necrosis factor alpha/cachectin and interleukin 1 beta initiate meningeal inflammation. *The Journal of experimental medicine* 1990; 172: 497-507.
51. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. *Archives of neurology* 2003; 60: 1524-1534.
52. Dray A. Tasting the inflammatory soup: role of peripheral neurons. *Pain Reviews* 1994; 1: 153-171.
53. Rang HP, Bevan SJ, Dray A. Nociceptive peripheral neurones: cellular properties. In: Wall PD, Melzack R, editors. *Textbook of Pain* ed. London: Churchill Livingstone, 1994; pp. 57-78.
54. Armstrong D. Pain. In: Erdos EG, Wilde AF, editors. *Bradykinin, kallidin and kallikrein. Handbook of experimental pharmacology*, Berlin: Springer, 1970; pp. 434-515.

55. Ferreira SH, Nakamura M, and Abreu Castro MS. The hyperalgesic effects of prostacyclin and PGE<sub>2</sub>. *Prostaglandins* 1978; 16: 31-37.
56. Sackett K, Cannon CA. Pain. In: Bullock BA, Itenze RL, editors. *Focus on path physiology*. Philadelphia: Lippincott, 2000; pp. 1047-1049.
57. Treede RD, Meyer RA, Raja SN, Campbell JN. Evidence for two different heat transduction mechanisms in nociceptive primary afferents innervating monkey skin. *The Journal of physiology* 1995; 483: 747-758.
58. Raj PP. Pain mechanisms. In: Raj PP. editor, *Pain Medicine: A Comprehensive Review*, 1st ed. Missouri: Mosby-Year Book, 1996: pp. 12-23.
59. Mackowiak PA, Bartlett JG, Borden EC. Concepts of fever: recent advances and lingering dogma. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* 1997; 25: 119-138.
60. Dinarello CA. Cytokines as endogenous pyrogens. In: Mackowiak PA. editor, *Fever: basic mechanisms and management*, 2nd ed. Philadelphia: Lippincott-Raven, 1997; pp. 87-116.
61. Taniguchi Y, Yokoyama K, Inui K, Deguchi Y, Furukawa K, Noda K. Inhibition of brain cyclooxygenase-2 activity and the antipyretic action of nimesulide. *European journal of pharmacology* 1997; 330: 221-229.
62. Katzung BG, Julius DJ. Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout. In: Katzung BG; editor. *Basic and clinical pharmacology* 9th ed. Sanfrancisco: Lange medical book/McGraw-Hill Companies, 2004: pp. 806-848.

63. Seivert K, Masferrer J, Zhang Y, Gregory S, Olson G, Hauser S, Leahy K, Perkins W, Isaksan P. Mediation of inflammation by cyclooxygenase-2. Agents and actions. Supplements 1995; 46: 41-50.
64. Verpoorte R. Exploration of nature's chemodiversity: the role of secondary metabolites as leads in drug development. Drug discovery today 1998; 3: 232-238.
65. Cowan MM. Plant products as antimicrobial agents. Clinical microbiology reviews 1999; 12: 564-582.
66. Akerele O. Summary of WHO guidelines for the assessment of herbal medicines. HerbalGram 1992; 28: 13-19.
67. Zakaria M, Mohd MA. Traditional Malay. Medicinal Plants 1994: 39-41.
68. Chaweewan J, Herbert B, Lennart K, Gunnar S. Ardisiacrispin A and B, Two utero-contracting Saponins from *Ardisia crispa*. Planta medica 1987; 53: 405-409.
69. Roslida AH, Kim KH. Anti-inflammatory and anti-hyperalgesic effects of *Ardisia crispa* Thunb. D.C. Pharmacognosy Magazine 2008; 4: 262-268.
70. Laupattarakasem P, Wangsrimongkol T, Surarit R, Hahnvajanawong C. In vitro and in vivo anti-inflammatory potential of *Cryptolepis buchanani*. Journal of ethnopharmacology 2006; 108: 349-354.
71. Pongboonrod S. Mai Thed Mung Muang Thai. Bangkok. Kaeseambunnakit Printing, Thailand 1995: 428-429.

72. Panthong A, Supraditaporn W, Kanjanapothi D, Taesotikul T, Reutrakul V. Analgesic, anti-inflammatory and venotonic effects of *Cissus quadrangularis* Linn. *Journal of ethnopharmacology* 2007; 110: 264–270.
73. Zakaria ZA, Wen LY, Rahman NIA, Ayub AHA, Sulaiman MR, Gopalan HK. Antinociceptive, Anti-Inflammatory and antipyretic properties of the aqueous extract of *Bauhinia purpurea* leaves in experimental animals. *Medical principles and practice* 2007; 16: 443-449.
74. Gupta M, Mazumder UK, Sambath Kumar R, Gomathi P, Rajeshwar Y, Kakoti BB, Tamil Selven V. Anti-inflammatory, analgesic and antipyretic effects of methanol extract from *Bauhinia racemosa* stem bark in animal models. *Journal of Ethnopharmacology* 2005; 98: 267-273.
75. Sosa S, Braca A, Altinier G, Loggia RD, Morelli I, Tubaro A. Topical anti-inflammatory activity of *Bauhinia tarapotensis* leaves. *Phytomedicine* 2002; 9: 646-653.
76. Larsen K, Larsen SS. *Bauhinia siamensis* (Leguminosae-Caesalpinioideae), an extraordinary new species from Thailand. *Natural History Bulletin Siam Society* 2002; 50: 99-104.
77. Larsen K, Larsen SS, Vidal JE. Leguminosae-Caesalpinioideae. In: Smitinand T, Larsen K, editors. *Flora of Thailand volume 4 part 1*, 1984; pp. 1-45.
78. Wunderlin R, Larsen K, Larsen SS. Reorganization of the Cercideae (Fabaceae: Caesalpinioideae). *Danske Biologiske Skrifter* 1987; 28: 1-40.
79. Brattsand R, Thalen A, Roempke K, Kallstrom L, Gruvstad E. Influence of 16 alpha,17 alpha-acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids. *Journal of steroid biochemistry* 1982; 16: 779-786.


80. Winter CA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs. *Proceedings of the Society for Experimental Biology and Medicine* 1962; 11: 544-547.
81. Di Martino MJ, Campbell GK, Wolff CE, Hanna N. The pharmacology of arachidonic acid induced rat paw edema. *Agents and actions* 1987; 21: 303-305.
82. Swingle KF, Shideman FE. Phases of inflammatory response to subcutaneous implantation of cotton pellet and their modification by certain anti-inflammatory agent. *The Journal of pharmacology and experimental therapeutics* 1972; 183: 226-234.
83. Bessey OA, Lowry OH, Brock MJ. Method for the determination of alkaline phosphatase with five cubic millimeters of serum. *Journal of biological chemistry* 1946; 164: 321-329.
84. Siegmund E, Cadmus R, LU G. A method for evaluating both non-narcotic and narcotic analgesics. *Proceedings of the Society for Experimental Biology and Medicine* 1957; 95: 729-731.
85. Vander WC, Margolin S. Analgesic tests based upon experimentally induced acute abdominal pain in rats. *Federation proceedings* 1956; 15: 494.
86. Collier HO, Dineen LC, Johnson CA, Schneider C. The abdominal constriction response and its suppression by analgesic drugs in the mouse. *British journal of pharmacology* 1968; 32: 295-310.
87. Nakamura H, Shimoda A, Ishi K, Kadokawa T. Central and peripheral analgesic action of non-acidic non steroid anti-inflammatory drugs in mice and rats. *Archives internationales de pharmacodynamic et de therapie* 1986; 282: 16-25.

88. Gray WD, Osterberg AC, Scute TJ. Measurement of the analgesic efficacy and potency of pentazocine by the D'Amour and Smith method. *Journal of pharmacological and experimental therapeutics* 1970; 172: 154-162.
89. Teotino UM, Friz LP, Ganduni A, Bella DD. Thio derivatives of 2,3-dihydro-4H-1,3-benzoxazin-4-one synthesis and pharmacological properties. *Journal of medicinal chemistry* 1963; 6: 248-250.
90. Crimmins EM, Finch CE. Infection, inflammation, height, and longevity. *Proceedings of the National Academy of Sciences of the United States of America* 2006; 103: 498-503.
91. Berenbaum F. Vioxx and cardiovascular events: a class effect?. *Joint, bone, spine : revue du rhumatisme* 2005; 72: 1-3.
92. Carlson RP, O'Neill-Davis L, Chang j, Lewis AJ. Modulation of mouse ear edema by cyclooxygenase and lipoxygenase inhibitors and other pharmacological agents. *Agents and actions* 1985; 17: 197-204.
93. Sedgwick AD, Willoughby DA. Animal models for testing drugs on inflammatory and hypersensitivity reaction. In: Dale MM, Foreman JC, editors. *Textbook of immunology* 2nd ed. Oxford: Blackwell Scientific, 1989; pp. 253-261.
94. Crunkhorn P, Meacock SC. Mediators of the inflammation induced in the rat paw by carrageenin. *British journal of pharmacology* 1971; 42: 392-402.
95. Vinegar R, Schreiber W, Hugo R. Biphasic development of carrageenin edema in rats. *The Journal of pharmacology and experimental therapeutics* 1969; 166: 96-103.

96. Di Rosa M, Sorrentino L. The mechanism of the inflammatory effect of carrageenin. *European journal of pharmacology* 1968; 4: 340-342.
97. Martin TR, Pistorese BP, Chi EY, Goodman RB, Matthay MA. Effects of leukotriene B<sub>4</sub> in the human lung. Recruitment of neutrophils into the alveolar spaces without a change in protein permeability. *The Journal of clinical investigation* 1989; 84: 1609-1619.
98. Soter NA, Lewis RA, Corey EJ, Austen KF. Local effects of synthetic leukotrienes (LTC<sub>4</sub>, LTD<sub>4</sub>, LTE<sub>4</sub>, and LTB<sub>4</sub>) in human skin. *The Journal of investigative dermatology* 1983; 80: 115-119.
99. Spector WG. The granulomatous inflammatory exudate. *International review of experimental pathology* 1969; 8: 1-55.
100. Olajide OA, Makinde JM, Awe SO. Effect of the aqueous extract of *Bridelia ferruginea* stem bark on carrageenan-induced edema and granuloma tissue formation in rats and mice. *Journal of ethnopharmacology* 1999; 66: 113-117.
101. Bailey PJ, Sturm A, Lopez-Ramos B. A biochemical study of the cotton pellet granuloma in the rat. Effects of dexamethasone and indomethacin. *Biochemical pharmacology* 1982; 31: 1213-1218.
102. Schimmer BP, Parker KL. Adrenocorticotrophic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Brunton LL, Lazo JS, Parker KL, editors. *Goodman & Gilman's the pharmacological basis of therapeutics* 11th ed. New York: Mc Graw-Hill, 2006; pp. 1587-1612.
103. Tapper H. The secretion of preformed granules by macrophages and neutrophils. *Journal of leukocyte biology* 1996; 59: 613-622.

104. Naik SR, Sheth UK. Studies on two new derivatives of *N*-aralkyl-*o*-ethoxybenzamides: Part II. Biochemical studies on their anti-inflammatory activity. *Indian journal of experimental biology* 1978; 16: 1175-1179.
105. Engblom D, Ek M, Saha S, Ericsson-Dahlstrand A, Jakobsson PJ. Prostaglandins as inflammatory messengers across the blood-brain barrier. *Journal of molecular medicine* 2002; 80: 5-15.
106. Ivanov AI, Romanovsky AA. Prostaglandin E<sub>2</sub> as a mediator of fever: Synthesis and catabolism. *Frontiers in bioscience: a journal and virtual library* 2004 9: 1977-1993.
107. Erichsen HK, Hao JX, Xu XJ, Munro GB. Comparative actions of the opioid analgesics morphine, methadone and codeine in rat models of peripheral and central neuropathic pain. *Pain* 2005; 116: 347-358.
108. Mitchell A, Akarasereenont P, Thiermermann C, Flower RJ, Van JR. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. *Proceeding of the National Academy of Sciences United States of America* 1993; 90: 11693-11697.
109. Bars DL, Gozariu M, Cadden SW. Animal Models of Nociception. *Pharmacological reviews* 2001; 53: 597-652
110. Fields HL. Analgesic Drugs. In: Day W, editor. *Pain*. 1st ed. New York: McGraw-Hill, 1987; pp. 272.
111. Lu Y, Pirec V, Yeomans DC. Differential antinociceptive effects of spinal opioids on foot withdrawal responses evoked by C fibre or A delta nociceptor activation. *British journal of pharmacology* 1997; 121: 1210-1216.

112. Rowbotham MC. Efficacy of opioids in neuropathic pain. In: Hansson PT, Fields HL, Hill RG, Marchettini P, editors. Neuropathic pain: pathophysiology and treatment. Seattle: International Association for the Study of Pain Press, 2001; pp. 203-213.
113. Li S, Ballou LR, Morham SG. Cyclooxygenase-2 mediates the febrile response of mice to interleukin-1 beta. Brain research 2001; 910: 163-173.



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่  
Copyright© by Chiang Mai University  
All rights reserved